Seeking Alpha

Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the...

Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the treatment is well-tolerated and effective when administered long-term. (See also: JMP, SA contributor weigh in on ACAD)
Comments (1)
  • duvas1952
    , contributor
    Comments (14) | Send Message
     
    How far up can the PPS of ACAD go?
    18 Jun 2013, 09:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs